依达拉奉与奥扎格雷钠治疗进展性脑梗死的临床效果浅析

摘要

Objective To investigate the clinical effect of edaravone and ozagrel on the progressive cerebral infarction.Methods In a hospital, from January 2014 to December 2015, 113 cases of progressive cerebral infarction were treated in two groups set by double-blind control method. The observation group 57 cases took ozagrel sodium combination edaravone treated, and the control group of 56 cases were only with simple application of sodium ozagrel conventional treatment. Followed up 1 to 3 months, compared the effect of two groups of patients.Results The observation group patients hypersensitive C-reactive protein, D-dimer indicators and NIHSS and ADL scores were significantly better than those of the control group(P<0.05), statistically significant; the total effective rate of the patients in the observation group was significantly higher in comparison,(P<0.05).Conclusion Taking edaravone and Ozagrel sodium common treatment in progressive cerebral infarction has a high security and effect.%目的：探讨依达拉奉与奥扎格雷钠用于进展性脑梗死患者治疗中的临床效果。方法选取2014年1月～2015年12月期间收治的进展性脑梗死患者113例，采取双盲对照法将其设置为2组，观察组57例，采取奥扎格雷钠联合应用依达拉奉进行治疗，对照组56例，仅单纯应用奥扎格雷钠常规治疗，随访观察1～3个月对比两组患者治疗效果。结果观察组患者治疗后超敏C反应蛋白、D-二聚体指标以及NIHSS与ADL评分均显著优于对照组（P＜0.05）；观察组患者治疗总有效率显著高于对照组（P＜0.05）。结论采取依达拉奉联合奥扎格雷钠共同治疗进展性脑梗死疗效确切，安全性较高。